Company Description
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.
The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.
It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California.
The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Country | United States |
Founded | 2007 |
Industry | Medical Care Facilities |
Sector | Healthcare |
Employees | 800 |
CEO | Dr. Daniel Virnich FACHE, M.B.A., M.D. |
Contact Details
Address: 18000 Studebaker Rd, Suite 800 Cerritos, California 90703 United States | |
Phone | 562-735-3226 |
Website | theoncologyinstitute.com |
Stock Details
Ticker Symbol | TOI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001799191 |
CUSIP Number | 68236X100 |
ISIN Number | US68236X1000 |
Employer ID | 84-3562323 |
SIC Code | 8011 |
Key Executives
Name | Position |
---|---|
Dr. Daniel Virnich FACHE, M.D., MBA | Chief Executive Officer |
Richard Alan Barasch | Executive Chairman of the Board |
Mihir Arunkumar Shah CPA | Chief Financial Officer and Principal Accounting Officer |
Hilda Agajanian M.B.A. | Founder and Chief Growth Officer |
Dr. Richy Agajanian M.D. | Founder and Chief Clinical Officer |
Jeremy N. Castle M.B.A. | Chief Operations Officer |
Rakesh Singh M.B.A. | Director of Technology |
Mark Hueppelsheuser Esq. | General Counsel |
Khurrum Shah J.D., M.B.A. | Senior Vice President of Compliance |
Julie Korinke | Director of Marketing and Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 21, 2024 | 8-K | Current Report |
Jun 13, 2024 | 8-K | Current Report |
Jun 3, 2024 | UPLOAD | Filing |
May 22, 2024 | 10-Q/A | [Amend] Quarterly report |
May 22, 2024 | 10-K/A | [Amend] Annual report |
May 15, 2024 | UPLOAD | Filing |
May 14, 2024 | 10-Q | Quarterly Report |
May 14, 2024 | 8-K | Current Report |
May 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
May 2, 2024 | DEF 14A | Other definitive proxy statements |